NATCO Pharma Ltd - Legal update on Ibrutinib Tablets

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has given update that the Appeals Court in the US has rejected its marketing partner Alvogen's appeal on Ibrutinib Tablets of 140 mg, 280 mg, 420 mg and 560 mg strength (proposed generic equivalents to Imbruvica® Tablets).

Natco and its co-development & marketing partner, Alvogen Pine Brook LLC, USA, are assessing their option on the way forward.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 581.35 as compared to the previous close of Rs. 582.20. The total number of shares traded during the day was 15284 in over 1715 trades.

The stock hit an intraday high of Rs. 587.95 and intraday low of 577.90. The net turnover during the day was Rs. 8919215.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 LegalUpdate Alvogen Appeal IbrutinibTablets